Daunomycin-arachidonic acid complex as a potential new antitumor agent.
A daunomycin-arachidonic acid complex (DM-C20:4) administered IV had a marked antitumor effect on the intraperitoneal growth of the AFP-producing hepatoma cell line, AH66. However, the daunomycin-arachidic acid (DM-C20:0) saturated fatty acid complex showed only the same antitumor effect on the AH66 cells as free daunomycin. It was demonstrated that the DM-C20:4 preparation maintained its chemical properties for some time in both plasma and liver homogenate.
D000818:Animals; D001095:Arachidonic Acids / Q000378:metabolism / Q000627:therapeutic use*; D003630:Daunorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000378:metabolism / Q000627:therapeutic use; D008114:Liver Neoplasms, Experimental / Q000188:drug therapy; D051381:Rats; D000509:alpha-Fetoproteins / Q000008:administration & dosage
D001095:Arachidonic Acids; D000509:alpha-Fetoproteins; C042135:daunomycin-arachidonic acid complex; D003630:Daunorubicin